A detailed history of Bellevue Group Ag transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Bellevue Group Ag holds 1,863,800 shares of NBIX stock, worth $252 Million. This represents 3.62% of its overall portfolio holdings.

Number of Shares
1,863,800
Previous 1,898,640 1.83%
Holding current value
$252 Million
Previous $261 Million 17.91%
% of portfolio
3.62%
Previous 4.37%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$114.58 - $153.15 $3.99 Million - $5.34 Million
-34,840 Reduced 1.83%
1,863,800 $215 Million
Q2 2024

Aug 14, 2024

SELL
$130.86 - $143.19 $20.6 Million - $22.5 Million
-157,234 Reduced 7.65%
1,898,640 $261 Million
Q1 2024

May 15, 2024

SELL
$130.4 - $143.74 $48.9 Million - $53.8 Million
-374,626 Reduced 15.41%
2,055,874 $284 Million
Q4 2023

Feb 14, 2024

SELL
$106.07 - $132.76 $16.2 Million - $20.3 Million
-153,050 Reduced 5.92%
2,430,500 $320 Million
Q3 2023

Nov 14, 2023

SELL
$94.02 - $117.1 $2.75 Million - $3.43 Million
-29,250 Reduced 1.12%
2,583,550 $291 Million
Q2 2023

Aug 14, 2023

SELL
$89.53 - $104.87 $44,765 - $52,435
-500 Reduced 0.02%
2,612,800 $246 Million
Q1 2023

May 15, 2023

SELL
$94.11 - $123.02 $15.1 Million - $19.7 Million
-159,994 Reduced 5.77%
2,613,300 $265 Million
Q4 2022

Feb 14, 2023

SELL
$106.72 - $127.06 $8.74 Million - $10.4 Million
-81,852 Reduced 2.87%
2,773,294 $331 Million
Q3 2022

Nov 14, 2022

BUY
$92.03 - $107.81 $997,697 - $1.17 Million
10,841 Added 0.38%
2,855,146 $303 Million
Q2 2022

Aug 11, 2022

SELL
$75.79 - $100.07 $13.6 Million - $17.9 Million
-179,146 Reduced 5.93%
2,844,305 $277 Million
Q1 2022

May 13, 2022

SELL
$72.45 - $94.81 $11.4 Million - $14.9 Million
-157,100 Reduced 4.94%
3,023,451 $283 Million
Q4 2021

Feb 10, 2022

BUY
$79.65 - $106.22 $14.1 Million - $18.7 Million
176,500 Added 5.88%
3,180,551 $271 Million
Q3 2021

Nov 12, 2021

SELL
$86.18 - $99.03 $1.18 Million - $1.36 Million
-13,700 Reduced 0.45%
3,004,051 $288 Million
Q2 2021

Aug 12, 2021

SELL
$89.43 - $102.27 $23 Million - $26.3 Million
-256,800 Reduced 7.84%
3,017,751 $294 Million
Q1 2021

May 12, 2021

SELL
$87.57 - $119.4 $10.7 Million - $14.6 Million
-122,100 Reduced 3.59%
3,274,551 $318 Million
Q4 2020

Feb 16, 2021

BUY
$86.91 - $108.33 $8.62 Million - $10.7 Million
99,200 Added 3.01%
3,396,651 $326 Million
Q3 2020

Nov 16, 2020

BUY
$96.16 - $135.15 $8.32 Million - $11.7 Million
86,551 Added 2.7%
3,297,451 $317 Million
Q2 2020

Aug 13, 2020

SELL
$85.09 - $130.36 $4.13 Million - $6.33 Million
-48,574 Reduced 1.49%
3,210,900 $392 Million
Q1 2020

May 14, 2020

SELL
$75.11 - $113.76 $4.42 Million - $6.7 Million
-58,900 Reduced 1.77%
3,259,474 $282 Million
Q4 2019

Feb 14, 2020

BUY
$86.8 - $118.57 $1.73 Million - $2.36 Million
19,900 Added 0.6%
3,318,374 $357 Million
Q3 2019

Nov 14, 2019

SELL
$83.82 - $101.5 $20.8 Million - $25.2 Million
-247,970 Reduced 6.99%
3,298,474 $297 Million
Q2 2019

Aug 14, 2019

BUY
$72.24 - $91.27 $255 Million - $322 Million
3,526,244 Added 17456.65%
3,546,444 $299 Million
Q1 2019

May 15, 2019

SELL
$69.31 - $91.53 $1.38 Million - $1.82 Million
-19,850 Reduced 49.56%
20,200 $1.78 Million
Q4 2018

Feb 12, 2019

SELL
$68.32 - $124.36 $102,479 - $186,540
-1,500 Reduced 3.61%
40,050 $2.86 Million
Q3 2018

Nov 13, 2018

SELL
$98.88 - $125.85 $197,760 - $251,700
-2,000 Reduced 4.59%
41,550 $5.11 Million
Q2 2018

Aug 07, 2018

SELL
$75.3 - $105.99 $760,530 - $1.07 Million
-10,100 Reduced 18.83%
43,550 $4.28 Million
Q1 2018

May 09, 2018

SELL
$75.88 - $92.43 $64,497 - $78,565
-850 Reduced 1.56%
53,650 $4.45 Million
Q4 2017

Feb 14, 2018

SELL
$58.53 - $77.59 $87,795 - $116,385
-1,500 Reduced 2.68%
54,500 $4.23 Million
Q3 2017

Nov 13, 2017

BUY
$47.97 - $61.28 $431,730 - $551,520
9,000 Added 19.15%
56,000 $3.43 Million
Q2 2017

Aug 14, 2017

BUY
N/A
47,000
47,000 $2.16 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Bellevue Group Ag Portfolio

Follow Bellevue Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.